<DOC>
	<DOC>NCT00468897</DOC>
	<brief_summary>The present pharmacokinetic study is designed to compare bioavailability and assess bioequivalence of two Rosiglitazone XR formulations produced at two different sites.Both formulations will be tested in fasting healthy volunteers</brief_summary>
	<brief_title>A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Healthy male or female aged 1855 years. BMI between 19 30 kg/m2 Exclusion criteria: Liver function tests above the upper limit Excessive alcohol consumption history History of Cigarette smoking Positive HIV, Hep B or C test Positive pregnancy test History of heparin sensitivity History of glucose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Alzheimers Disease</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>healthy volunteers</keyword>
</DOC>